This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Cell Medica/UCL TCR Program
Cell Medica Ltd.
Cell Medica and University College London (UCL) will utilize UCL's novel T cell receptor (TCR) technology to generate modified TCR products. Based on Cell Medica's portfolio, we assume these will be cell-based therapies expressing modified TCRs.
We will update this record as more details become available.
Cell Medica and University College London
In August 2016, Cell Medica has signed a research collaboration with UCL (University College London) aiming to utilize UCLs novel T cell receptor (TCR) technology to generate modified TCR products for the treatment of cancer. The collaboration also provides Cell Medica with an exclusive worldwide option and license agreement for these technologies as well as TCR gene sequences for the development and commercialization of specific products. UCL will conduct the preclinical and early clinical research under the guidance of a Joint Steering Committee. Cell Medica will support the product development work with its substantial experience in manufacturing clinical-grade cell therapies and establishing robust production processes suitable for industrial scale-up. Following completion of successful first-in-man studies, the products will transfer to Cell Medica for later-stage clinical development and commercialization.
Cell Medica...See full deal structure in Biomedtracker
Partners: University College London
Cell Medica/UCL TCR Program News
Scrip Altor BioScience Corp.
Additional information available to subscribers only: